Diarrhea News and Research

Latest Diarrhea News and Research

Safe living guidelines for transplant recipients

Keeping pets healthy can reduce infection risks for people who have received solid organ transplants and veterinarians should be seen as an integral part of the healthcare team. That's just one of the key pieces of advice from a safe living article published in an infectious diseases supplement in the American Journal of Transplantation.

18 Dec 2009

Study explains Salmonella's infection strategy

Salmonella are highly adaptive bacteria. They can live in the presence and absence of oxygen and thus propagate in the gut. The ingestion by humans occurs mainly via contaminated egg dishes such as mayonnaise or raw milk products as well as meat or sausages. Infections with Salmonella lead to severe diarrhea and fever, particularly in patients harbouring a compromised immune system.

17 Dec 2009

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

PHT Corporation announced that Sanofi Pasteur is using PHT’s LogPad® System and StudyWorksTM online portal for a Phase II trial to develop a vaccine against the Clostridium difficile bacterium.

17 Dec 2009

Cubist Pharmaceuticals acquires Calixa Therapeutics

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc.,

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc.

16 Dec 2009

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Cumberland Pharmaceuticals Inc. (CPIX) today announced new top-line results for a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to similar products in liquid forms.

16 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).

15 Dec 2009

INS cites FDA-approved Totect antidote for anthracycline extravasations

The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation. Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.

15 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist’s US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Positive interim results of ARRY-380 in Phase 1 trial announced

Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

13 Dec 2009

Diarrhea News and Research

Latest Diarrhea News and Research

Safe living guidelines for transplant recipients

Study explains Salmonella's infection strategy

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Cubist Pharmaceuticals acquires Calixa Therapeutics

FDA Advisory Committee votes against the approval of Tarceva

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Positive results from study comparing exenatide once weekly to BYETTA

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

INS cites FDA-approved Totect antidote for anthracycline extravasations

ZYPREXA RELPREVV approved by FDA

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Pfizer announces results from studies evaluating neratinib

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Combination therapy improves overall survival in women with advanced breast cancer

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Positive interim results of ARRY-380 in Phase 1 trial announced

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in